Prospective Grant of Exclusive License: Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease and Cognitive Disorders

Riepilogo

This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide licenses to practice the inventions embodied in U.S. Patent 5,171,750, entitled ``Substituted Phenserines as Specific Inhibitors of Acetylcholinesterase'' and U.S. Patent Applications SN 07/861,329 and 08/096,207, both entitled ``Phenylcarbamates of (-)- Eseroline, (-)-N1-Noreseroline and (-)-N1-Benzylnoreseroline: Selective Inhibitors of Acetyl and/or Butyrylcholinesterase,'' 07/765,766, entitled ``Thiapysovenine and Carbamate Analogs, Pharmaceutical Compositions and Method for Inhibiting Cholinesterases,'' 07/845,081 and 08/182,301, both entitled ``Carbamate Analogs of Thiaphysovenine, Pharmaceutical Compositions, and Method for Inhibiting Cholinesterases,'' and 07/980,399, entitled ``Method for Treating Cognitive Disorders With Phenserine'' to CURE, Inc. of Baltimore, Maryland. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and cond